Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study

Abstract

ObjectiveThe aim of this retrospective study was to evaluate the efficacy and prognostic factors of bortezomib and dexamethasone (BD) chemotherapy regimen in the treatment of newly diagnosed multiple myeloma (MM) patients in our hospital.MethodsA total of 47 newly diagnosed MM patients treated in our hospital from May 2010 to September 2016 were included in this study. All the enrolled patients received at least two cycles of BD chemotherapy regimen.ResultsThe overall response rate after treatment was 68.5% with a complete response of 23.4%, very good partial response of 17.0%, partial response of 21.3% and minor response of 6.8%. The median time of overall survival (OS), progression-free survival (PFS) and time to progression (TTP) of the treated patients were 36.0, 19.0 and 18.0 months, respectively; the mean OS, PFS and TTP were 36.0, 19.3 and 18.8 months, respectively. Though some adverse events had occurred, none of the patients was discontinued from treatment. Level of albumin, β2-microglobulin and cytogenetic abnormalities were prognostic factors for OS, and plasma cell percentage in bone marrow, β2-microglobulin and cytogenetic abnormalities were prognostic factors for PFS as revealed by log-rank test of univariate analysis; no prognostic factors for OS and PFS were detected by COX regression of multivariate analysis.ConclusionOur study demonstrated that BD regimen was effective and well tolerated in newly diagnosed MM patients, and prognostic factors for patients’ survival include level of albumin, plasma cell percentage in bone marrow, β2-microglobulin and cytogenetic abnormalities.

Upregulation of lncRNA NR_046683 Serves as a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma

“…MM is a highly heterogenous clonal disease with complex molecular biological characteristics that leads to renal injury, anemia and bone destruction. Along with microenvironmental changes, abnormalities in biomarkers and cytogenetics may already be present before the presentation of symptoms appear (Chen R. et al, 2017; Cowan et al, 2018). Therefore, the search for new indicators for early clinical diagnosis, therapeutic response and prognostic prediction is an urgent issue.…”

The combination of serum calcium levels, neutrophil‑to‑lymphocyte ratio and platelet count in the prognosis of multiple myeloma: A retrospective cohort study and review of the literature

“…Cai et al (5) suggested that a high albumin-to-globulin ratio was associated with an improved survival time (5). Qian et al (6) and Chen et al (7) indicated that a high percentage of abnormal plasma cells in the bone marrow were highly associated with a poor prognosis. Qian et al (6) also demonstrated that a high serum calcium level was a poor prognostic factor for OS.…”

Construction of a prognosis‑associated long noncoding RNA‑mRNA network for multiple myeloma based on microarray and bioinformatics analysis

“…The expression levels of several lncrnas have been reported in multiple myeloma (MM); their clinical significance, biological functions and potential molecular mechanisms in the disease have also been investigated (14)(15)(16). MM is the second most frequent hematological malignancy, and accounts for ~10% of all such malignancies (17)(18)(19)(20)(21)(22). immunomodulatory drugs (such as lenalidomide and pomamide), proteasome inhibitors (such as bortezomib and carfilzomib) and monoclonal antibodies have significantly increased the survival rate of patients with MM over the past decade (23)(24)(25); however, the treatment of relapsed and partially refractory patients remains challenging.…”